Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20117016 | 1.00 | MAPT (0.49) | MAPTLMNANPC1HTTHDAC4 | |
| SCHEMBL20116921 | 0.88 | MAPT (0.48) | MAPTLMNANPC1HTTSCD5 | |
| SCHEMBL22358307 | 0.87 | MAPT (0.47) | MAPTLMNANPC1HTTSCD5 | |
| SCHEMBL22358167 | 0.84 | MAPT (0.45) | MAPTLMNANPC1HTTSCD5 | |
| SCHEMBL22357796 | 0.83 | SCD5 (0.45) | MAPTLMNANPC1HTTHDAC4 | |
| SCHEMBL20116370 | 0.83 | MAPT (0.51) | MAPTLMNANPC1HTTHDAC4 | |
| SCHEMBL20676409 | 0.82 | MAPT (0.43) | MAPTLMNANPC1HTTSCD5 | |
| SCHEMBL22358263 | 0.82 | GRM5 (0.44) | GPR119SCD5 | |
| SCHEMBL18624608 | 0.81 | MAPT (0.62) | MAPTLMNANPC1HTTHDAC4 | |
| SCHEMBL22358277 | 0.81 | GPR119 (0.45) | LMNANPC1HTTHDAC4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MAPT 22/4885LMNA 1966/4885NPC1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.